NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical need, reported third quarter 2025 results and outlined upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte(TM) study in cutaneous T-cell lymphoma (CTCL). CEO Christopher J. Schaber, PhD, confirmed that the first Data Monitoring Committee review found no safety concerns for HyBryte(TM), maintaining a consistent safety profile across trials. With $10.5 million in cash as of Sept. 30, 2025, Soligenix expects its operating runway to extend through 2026 while evaluating strategic options to…







